Barclays Maintains Overweight on West Pharmaceutical Servs, Raises Price Target to $500
Benzinga Newsdesk 1 day ago
Analyst RatingsNewsPrice Target
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.
Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Overweight and raises the price target from $440 to $500.